Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Novo Nordisk Rejects Public Citizen Assertion on Victoza

Novo Nordisk A/S said it rejects assertions by the U.S. group Public Citizen that the diabetes drug Victoza should be pulled from the market.

“Novo Nordisk is committed to patient safety and rejects Public Citizen’s assertion that the benefits of Victoza are outweighed by its risks,” the Bagsvaerd, Denmark-based company said in an e-mailed statement late yesterday.

Public Citizen said yesterday the drug puts patients at higher risk of thyroid cancer, pancreatitis and other problems.

“In the two years since Victoza was approved, Novo Nordisk has continued to work closely with the FDA and the medical community to monitor the benefits and appropriate use of Victoza,” Novo Nordisk said. “Our experience in those two years does not support the Public Citizen call to deprive patients of the benefits of Victoza.”

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.